Recent research indicates that the early addition of ezetimibe, a cholesterol-lowering medication, to statin therapy may significantly enhance post-heart attack outcomes. Published in the April 2025 edition of the Journal of the American College of Cardiology, the study analyzed data from over 35,000 patients hospitalized for heart attacks in Sweden between 2015 and 2022.
The findings suggest that patients who commenced ezetimibe within 12 weeks of their heart attack experienced fewer major adverse cardiovascular events (MACE)—including death, recurrent heart attacks, and strokes—compared to those who delayed treatment or did not receive ezetimibe at all. Specifically, the one-year incidence of MACE was notably lower in the early treatment group, indicating a potential benefit of prompt intervention.
Ezetimibe works by inhibiting cholesterol absorption in the intestines, thereby reducing low-density lipoprotein (LDL) cholesterol levels. The study posits that initiating combination therapy with statins and ezetimibe at an early stage could lead to better cholesterol management and improved patient outcomes. It highlights that a significant portion of post-heart attack patients do not achieve their LDL cholesterol targets with statins alone.
Experts have noted that while lowering cholesterol is crucial for preventing subsequent cardiovascular events, it is also essential to address underlying factors like inflammation. Some healthcare professionals advocate for a broader approach that includes lifestyle modifications and nutritional considerations alongside medication.
In light of these findings, the authors recommend revising clinical care pathways for heart attack patients to incorporate early combination therapy as a standard practice, potentially even before hospital discharge. This approach aims to optimize patient recovery and reduce the risk of further cardiovascular complications.